[HTML][HTML] Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils

MT Krauth, A Böhm, H Agis, K Sonneck… - Experimental …, 2007 - Elsevier
OBJECTIVE: Mylotarg (gemtuzumab ozogamicin [GO]) has recently been introduced as a
novel CD33-targeting drug in clinical hematology. However, despite efficacy, GO produces
significant side effects including an infusion syndrome. We have recently shown that mast
cells (MCs) and basophils (BAs) express CD33. In the present study, we investigated the
effects of GO on growth and mediator secretion in MCs and BAs. METHODS: Growth-
inhibitory effects of GO on neoplastic MCs (HMC-1) and BAs (KU812) as well as cord blood …